Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
P/B ratio for Lexicon Pharmaceuticals, Inc. (LXRX)
P/B ratio as of 2023: 3.63
According to Lexicon Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.63. At the end of 2022 the company had a P/B ratio of -0.20.
P/B ratio history for Lexicon Pharmaceuticals, Inc. from 1999 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 3.63 |
| 2022 | -0.20 |
| 2021 | -0.39 |
| 2020 | 2.42 |
| 2019 | -0.33 |
| 2018 | -0.48 |
| 2017 | 19.93 |
| 2016 | 9.13 |
| 2015 | 4.82 |
| 2014 | 1.71 |
| 2013 | -0.92 |
| 2012 | 4.06 |
| 2011 | 1.48 |
| 2010 | 1.77 |
| 2009 | 1.51 |
| 2008 | 1.03 |
| 2007 | 1.18 |
| 2006 | 2.82 |
| 2005 | 2.72 |
| 2004 | 4.04 |
| 2003 | 2.01 |
| 2002 | 1.45 |
| 2001 | 2.65 |
| 2000 | 3.33 |
| 1999 | 56.09 |